Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics

被引:24
作者
Chen, Po-Yu [1 ,2 ,3 ,4 ,5 ]
Chen, Chun-Hsin [5 ,9 ]
Chang, Chin-Kuo [3 ,6 ]
Kao, Chung-Feng [7 ]
Lu, Mong-Liang [4 ,5 ]
Lin, Shih-Ku [2 ,4 ]
Huang, Ming-Chyi [2 ,4 ,8 ]
Hwang, Ling-Ling [1 ,9 ]
Mondelli, Valeria [3 ]
机构
[1] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan
[2] Taipei City Hosp, Dept Psychiat, Taipei City Psychiat Ctr, 309 Song De Rd, Taipei 110, Taiwan
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
[4] Taipei Med Univ, Sch Med, Dept Psychiat, Coll Med, Taipei, Taiwan
[5] Taipei Med Univ, Wan Fang Hosp, Dept Psychiat, Taipei, Taiwan
[6] Univ Taipei, Dept Hlth & Welf, Taipei, Taiwan
[7] Natl Chung Hsing Univ, Dept Agron, Coll Agr & Nat Resources, Taichung, Taiwan
[8] Taipei Med Univ Hosp, Psychiat Res Ctr, Taipei, Taiwan
[9] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, 250 Wuxing St, Taipei 110, Taiwan
关键词
orexin-A; schizophrenia; antipsychotics; metabolic syndrome; clozapine; AUTONOMIC NERVOUS-SYSTEM; PLASMA OREXIN; INSULIN-RESISTANCE; HYPERTHERMIC REACTIONS; HYPOCRETIN-1; LEVELS; CEREBRAL INJECTION; GLUCOSE-TOLERANCE; LEPTIN; PREVALENCE; GHRELIN;
D O I
10.1093/ijnp/pyy075
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The role of orexin-A in regulating metabolic homeostasis has been recognized, but its association with antipsychotic-induced metabolic abnormalities remains unclear. We investigated the association between orexin-A levels and metabolic syndrome in patients with schizophrenia treated with clozapine or less obesogenic antipsychotics compared with nonpsychiatric controls. Methods: Plasma orexin-A levels and metabolic parameters were determined in 159 patients with schizophrenia: 109 taking clozapine; 50 taking aripiprazole, amisulpride, ziprasidone, or haloperidol; and 60 nonpsychiatric controls. Results: Orexin-A levels were significantly higher in the group taking less obesogenic antipsychotics, followed by the clozapine group and the controls (F = 104.6, P <. 01). Higher orexin-A levels were correlated with better metabolic profiles in the patient groups but not in the controls. Regression analyses revealed that the patients with higher orexin-A levels had significantly lower risk of metabolic syndrome (adjusted odds ratio [OR] = 0.04, 95% CI: 0.01-0.38 for the 2nd tertile; OR = 0.04, 95% CI: 0.01-0.36 for the 3rd tertile, compared with the first tertile), after adjustment for age, sex, smoking history, types of antipsychotics (clozapine vs less obesogenic antipsychotics), duration of antipsychotic treatment, and disease severity. Conclusions: Our results revealed that the orexin-A level was upregulated in patients with schizophrenia treated with antipsychotics, especially for the group taking less obesogenic antipsychotics. Furthermore, higher orexin-A levels were independently associated with better metabolic profiles. These observations suggest that an upregulation of orexin-A has a protective effect against the development of metabolic abnormalities in patients with schizophrenia receiving antipsychotic treatment.
引用
收藏
页码:28 / 36
页数:9
相关论文
共 50 条
  • [21] Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia An Egyptian Study
    El-Gabry, Dina M. Aly
    Aziz, Karim Abdel
    Okasha, Tarek
    Azzam, Hanan
    Okasha, Ahmed
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (01) : 27 - 33
  • [22] Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
    Boiko, Anastasiia S.
    Mednova, Irina A.
    Kornetova, Elena G.
    Goncharova, Anastasiia A.
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Ivanova, Svetlana A.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):
  • [23] Metabolic syndrome in antipsychotic naive patients diagnosed with schizophrenia
    Grover, Sandeep
    Nebhinani, Naresh
    Chakrabarti, Subho
    Parakh, Preeti
    Ghormode, Deepak
    EARLY INTERVENTION IN PSYCHIATRY, 2012, 6 (03) : 326 - 331
  • [24] Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia
    Grover, Sandeep
    Padmavati, R.
    Sahoo, Swapnajeet
    Gopal, Subhashini
    Nehra, Ritu
    Ganesh, Arthi
    Raghavan, Vijaya
    Sankaranarayan, Anoop
    PSYCHIATRY RESEARCH, 2019, 278 : 56 - 64
  • [25] Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
    Boiko, Anastasiia S.
    Mednova, Irina A.
    Kornetova, Elena G.
    Gerasimova, Valeria I.
    Kornetov, Alexander N.
    Loonen, Anton J. M.
    Bokhan, Nikolay A.
    Ivanova, Svetlana A.
    PHARMACEUTICALS, 2021, 14 (05)
  • [26] Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
    Mednova, Irina A.
    Boiko, Anastasiia S.
    Kornetova, Elena G.
    Parshukova, Daria A.
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Loonen, Anton J. M.
    Ivanova, Svetlana A.
    METABOLITES, 2020, 10 (10) : 1 - 13
  • [27] Circulating levels of ghrelin, galanin, and orexin-A orexigenic neuropeptides in obstructive sleep apnea syndrome
    Ozturk, Onder
    Cebeci, Defne
    Sahin, Ugur
    Tuluceoglu, Eda Evgen
    Calapoglu, Nilufer Sahin
    Gonca, Taner
    Calapoglu, Mustafa
    SLEEP AND BREATHING, 2022, 26 (03) : 1209 - 1218
  • [28] Cytokine levels in schizophrenia patients with metabolic syndrome
    Boiko, A.
    Mednova, I.
    Kornetova, E.
    Ivanova, S.
    EUROPEAN PSYCHIATRY, 2020, 63 : S33 - S33
  • [29] Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
    Mehrul Hasnain
    Sonja K. Fredrickson
    W. Victor R. Vieweg
    Anand K. Pandurangi
    Current Diabetes Reports, 2010, 10 : 209 - 216
  • [30] Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine
    Chen, Xinyue
    Wu, Xinyan
    Zhang, Wenjing
    Liao, Kaike
    Yu, Rui
    Lui, Su
    Liu, Nian
    JOURNAL OF PSYCHIATRIC RESEARCH, 2025, 181 : 245 - 252